Cargando…
P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis
P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coronary intervention (PCI) in the modern era. Clinical trials have shown that it could lower the risk of bleeding complications without increased ischemic events as compared to standard dual antiplatelet...
Autores principales: | Feng, Wen-Han, Chang, Yong-Chieh, Lin, Yi-Hsiung, Chen, Hsiao-Ling, Chen, Chun-Yin, Lin, Tsung-Han, Lin, Tzu-Chieh, Chang, Ching-Tang, Kuo, Hsuan-Fu, Chang, Hsiu-Mei, Chu, Chih-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958698/ https://www.ncbi.nlm.nih.gov/pubmed/37259380 http://dx.doi.org/10.3390/ph16020232 |
Ejemplares similares
-
Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
por: Feng, Wen-Han, et al.
Publicado: (2022) -
Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease
por: Kao, Chih-Chin, et al.
Publicado: (2021) -
Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
por: Han, Jialun, et al.
Publicado: (2023) -
Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021) -
Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)